| Size | Price | |
|---|---|---|
| 100mg | ||
| 250mg | ||
| 500mg | ||
| Other Sizes |
| Targets |
ERβ
|
|---|---|
| ln Vitro |
7β-Hydroxy-epi-androsterone (1, 10 and 100 nM, 72 hours) suppresses MCF-7 and MDA-MB-231 cell proliferation in the presence of E2 (10 nM) [2]. 7β-Hydroxy-epi-androsterone (1, 10 and 100 nM, 48 hours) causes G0/G1 cell cycle arrest in MCF-7 and MDA-MB-231 cells [2]. 7β-Hydroxy-epi-androsterone (1, 10 and 100 nM, 48 hours) promotes apoptosis in MCF-7 cells in the presence of E2 (10 nM) [2]. 7β-Hydroxy-epi-androsterone (1, 10 and 100 nM, 24 hours) binds to ERβ and inhibits transactivation in MDA-MB-231 cells [2].
|
| ln Vivo |
In rats with DSS-induced colitis, 7β-Hydroxy-epi-androsterone (ip; once daily for seven days) demonstrated anti-inflammatory benefits[3]. In rats with Alzheimer's disease, 7β-Hydroxyepi-androsterone (0.1 mg/kg subcutaneously twice daily for 10 days) shows protective benefits against glial cell death and inflammatory neurodegeneration[4].
|
| Cell Assay |
Apoptosis Analysis[2]
Cell Types: MCF-7 cells Tested Concentrations: 1, 10 and 100 nM (in presence of 10 nM E2) Incubation Duration: 48 h Experimental Results: Increased cell apoptosis in presence of E2. |
| Animal Protocol |
Animal/Disease Models: Rat with DSS-induced colitis[3]
Doses: 0.01, 0.1 and 1 mg/kg Route of Administration: intraperitoneal (ip) injection (ip), one time/day for 7 days. Experimental Results: Increased in COX-2 and PGE synthase expression. Increased colonic tissue levels of 15d-PGJ2 levels. |
| References |
[1]. Christophe Ricco, et al. Synthesis of 7β-hydroxy-epiandrosterone. Steroids. Volume 76, Issues 1-2, January 2011, Pages 28-30.
[2]. Sandra N, et al. The DHEA metabolite 7β-hydroxy-epiandrosterone exerts anti-estrogenic effects on breast cancer cell lines. Steroids. 2012 Apr;77(5):542-51. [3]. Hennebert O, et al. Anti-inflammatory effects and changes in prostaglandin patterns induced by 7beta-hydroxy-epiandrosterone in rats with colitis. J Steroid Biochem Mol Biol. 2008 Jun;110(3-5):255-62. [4]. Dudas B, et al. Protection against inflammatory neurodegeneration and glial cell death by 7beta-hydroxy epiandrosterone, a novel neurosteroid. Neurobiol Dis. 2004 Mar;15(2):262-8. |
| Molecular Formula |
C19H30O3
|
|---|---|
| Molecular Weight |
306.44
|
| CAS # |
25848-69-5
|
| SMILES |
C12(C3([H])C([H])([H])C([H])([H])C4(C(C(C([H])([H])C4([H])C3([H])C(O[H])([H])C([H])([H])C1(C(C(C(C2([H])[H])([H])[H])(O[H])[H])([H])[H])[H])([H])[H])=O)C([H])([H])[H])C([H])([H])[H]
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2633 mL | 16.3164 mL | 32.6328 mL | |
| 5 mM | 0.6527 mL | 3.2633 mL | 6.5266 mL | |
| 10 mM | 0.3263 mL | 1.6316 mL | 3.2633 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
